Trial Profile
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Navtemadlin (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 01 Mar 2024 Planned End Date changed from 31 Dec 2023 to 28 Feb 2025.
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 03 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.